Angelalign Technology (SEHK:6699) Is Getting Fresh Attention, What Is The Market Weighing?

Angelalign Technology earnings update

Angelalign Technology (SEHK:6699) reported half year 2026 earnings that caught investor attention, with sales of US$230.7 million and net income of US$27.25 million compared with the same period a year earlier.

Angelalign Technology’s recent half year earnings sit against a strong rebound in the stock, with a 30 day share price return of 12.64% and a 90 day share price return of 25.61%. The 3 year total shareholder return of 82.77% contrasts sharply with a 5 year total shareholder return that is down 73.40%, suggesting momentum has improved more recently compared with the longer term picture.

Scan beyond Angelalign Technology and review other healthcare stocks with strong recent momentum using our hand picked 614 high quality undiscovered gems as a starting point for further research.

After a sharp rebound and fresh earnings in the bag, Angelalign Technology now trades close to analyst targets while some intrinsic estimates sit higher. Is the recent price already reflecting fair value, or is there still a gap?

Price-to-Earnings of 69x for Angelalign Technology: Is it justified?

On a simple multiple check, Angelalign Technology looks expensive. The stock trades on a P/E of 69x while the Hong Kong Medical Equipment industry sits at 16.8x and the peer group average is 28.8x.

The P/E ratio compares the current share price with earnings per share. For a company such as Angelalign Technology, which operates in clear aligners and dental equipment, a higher P/E can signal that the market is pricing in strong profit growth or a premium business profile.

That premium is clear here. The current 69x P/E is more than double the peer average of 28.8x and more than four times the wider industry at 16.8x. It also sits well above an estimated fair P/E of 20.6x. This indicates a level that the market could move towards if expectations cool or earnings catch up more slowly than implied by the current price.

For investors who want to understand how that fair level is calculated and where the gap comes from, Explore the SWS fair ratio for Angelalign Technology

Result: Preferred multiple of Price-to-Earnings of 69x (OVERVALUED)

However, there are clear risks if Angelalign Technology’s earnings growth slows, or if sentiment toward high multiple healthcare stocks shifts more quickly than expected.

Find out about the key risks to this Angelalign Technology narrative.

Another view on Angelalign Technology’s value

While the P/E of 69x suggests Angelalign Technology is expensive compared with peers, our DCF model points to a fair value of about HK$82.07 per share versus the current HK$90. That implies the stock looks overvalued on cash flows. Which signal matters more for you?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Angelalign Technology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 266 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around Angelalign Technology leave you unsure, move quickly from headline impressions to your own data driven view. To balance both sides of the story, check the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Angelalign Technology?

If Angelalign Technology has sharpened your focus, broaden your watchlist now. Fresh ideas from quality screeners can highlight stocks you may wish you had seen earlier.

• Spot potential bargains backed by solid fundamentals with the 266 high quality undervalued stocks that filters for quality and attractive pricing.
• Focus on strength and resilience using the list of solid balance sheet and fundamentals (430 results) which highlights companies with sturdier financial foundations.
• Prioritise stability while still seeking upside by reviewing the 297 resilient stocks with low risk scores that surfaces stocks with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com